PP
BDTX icon

PDT Partners’s Black Diamond Therapeutics BDTX Stock Holding History

PDT Partners’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-66,168
Closed -$183K – 960
2022
Q1 		$183K Sell
66,168
-7,868
-11% -$28.7K 0.02% 825
2021
Q4 		$395K Sell
74,036
-27,844
-27% -$195K 0.03% 599
2021
Q3 		$862K Sell
101,880
-10,087
-9% -$99.6K 0.06% 371
2021
Q2 		$1.36M Buy
111,967
+44,223
+65% +$874K 0.09% 320
2021
Q1 		$1.64M Buy
67,744
+42,744
+171% +$1.15M 0.12% 289
2020
Q4 		$801K Buy
25,000
+14,994
+150% +$493K 0.05% 369
2020
Q3 		$302K Buy
+10,006
New +$305K 0.02% 551

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

PDT Partners's BDTX Position: Q2 2022 in Review

PDT Partners sold out of Black Diamond Therapeutics (BDTX) in Q2 2022, closing a stake of 66,168 shares — an estimated $183K sold.

PDT Partners first reported a position in BDTX in Q3 2020 and held it in 7 quarters. The position peaked at $1.64M in Q1 2021. 74 funds tracked by Wall St. Rank hold BDTX as of Q2 2022.

  • PDT Partners reported no remaining Black Diamond Therapeutics position as of Q2 2022 after selling out during the quarter.
  • PDT Partners sold 66,168 Black Diamond Therapeutics shares in Q2 2022, an estimated $183K.
  • PDT Partners first reported a position in Black Diamond Therapeutics in Q3 2020 and held it in 7 quarters.
  • PDT Partners's Black Diamond Therapeutics position peaked at $1.64M in Q1 2021.
  • 74 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.